Science & Enterprise subscription

Follow us on Twitter

  • In one of its first actions, the Biden administration rejoined the United States in the World Health Organization,… https://t.co/gpHTTr70DP
    about 13 hours ago
  • New post on Science and Enterprise: U.S. Rejoins WHO, Participates in Int’l Vaccine Project https://t.co/bBUZr5UzSg #Science #Business
    about 13 hours ago
  • A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower ris… https://t.co/EPYrP8wElE
    about 17 hours ago
  • New post on Science and Enterprise: Antibodies Prevent Covid-19 Symptoms in Long-Term Care https://t.co/sePqojZMVd #Science #Business
    about 17 hours ago
  • Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
    about 1 day ago

Please share Science & Enterprise

Crispr Heart Disease Biotech Raises $94M in New Funds

Editing DNA

A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds

Biotech Licenses mRNA Technology for Aging

Hands of older person

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Drug Maker Gains Access to Hidden Protein Immunotherapies

T-cells and cancer cells

Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies

Moderna Developing Flu, HIV, Nipah Vaccines

Syringe and three vials

Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines

Vaccine Shown Active Against New Covid-19 Variants

mRNA vaccine graphic

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

CureVac, Bayer Partner on Covid-19 Vaccine Supply

Syringe in hand

Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine. . . . → Read More: CureVac, Bayer Partner on Covid-19 Vaccine Supply

Synthetic Biology Company Raises $105M in New Funds

DNA chip graphic

A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round. . . . → Read More: Synthetic Biology Company Raises $105M in New Funds

FDA Issues Precision Genomic Drug Guidance

DNA analysis graphic

The U.S. Food and Drug Administration issued draft administrative and procedural guidelines for genetic disorders treated with precise gene therapies. . . . → Read More: FDA Issues Precision Genomic Drug Guidance

Trial OKed for Rare Disease Gene Therapy

Nerve cells illustration

A start-up biotech company says it received clearance from the Food and Drug Administration to begin a clinical trial of its gene therapy for Krabbe disease. . . . → Read More: Trial OKed for Rare Disease Gene Therapy

Device-Aided Covid-19 Vaccine Invokes Immune Response

SARS-CoV-2 and cell

Results from an early clinical trial show a Covid-19 vaccine using an electronic device to boost uptake in cells is safe and generates an immune-system response. . . . → Read More: Device-Aided Covid-19 Vaccine Invokes Immune Response